These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

658 related items for PubMed ID: 22246317

  • 1. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M.
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [Abstract] [Full Text] [Related]

  • 2. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.
    Gloesenkamp CR, Nitzsche B, Ocker M, Di Fazio P, Quint K, Hoffmann B, Scherübl H, Höpfner M.
    Int J Oncol; 2012 Mar; 40(3):876-88. PubMed ID: 22075556
    [Abstract] [Full Text] [Related]

  • 3. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
    Breinig M, Mayer P, Harjung A, Goeppert B, Malz M, Penzel R, Neumann O, Hartmann A, Dienemann H, Giaccone G, Schirmacher P, Kern MA, Chiosis G, Rieker RJ.
    Clin Cancer Res; 2011 Apr 15; 17(8):2237-49. PubMed ID: 21372220
    [Abstract] [Full Text] [Related]

  • 4. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M, Baradari V, Huether A, Schöfl C, Scherübl H.
    Endocr Relat Cancer; 2006 Mar 15; 13(1):135-49. PubMed ID: 16601284
    [Abstract] [Full Text] [Related]

  • 5. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun 15; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 7. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM.
    Cancer; 2011 Sep 15; 117(18):4141-54. PubMed ID: 21387274
    [Abstract] [Full Text] [Related]

  • 8. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
    Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, Palombella VJ, Fritz CC.
    Oncogene; 2011 Jun 02; 30(22):2581-6. PubMed ID: 21258415
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 02; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 10. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.
    Mayer P, Harjung A, Breinig M, Fischer L, Ehemann V, Malz M, Scherübl H, Britsch S, Werner J, Kern MA, Bläker H, Schirmacher P, Bergmann F.
    Endocr Relat Cancer; 2012 Jun 02; 19(3):217-32. PubMed ID: 22194440
    [Abstract] [Full Text] [Related]

  • 11. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Calero R, Morchon E, Martinez-Argudo I, Serrano R.
    Cancer Lett; 2017 Oct 10; 406():1-11. PubMed ID: 28774796
    [Abstract] [Full Text] [Related]

  • 12. Anti-apoptotic effect of heat shock protein 90 on hypoxia-mediated cardiomyocyte damage is mediated via the phosphatidylinositol 3-kinase/AKT pathway.
    Wang W, Peng Y, Wang Y, Zhao X, Yuan Z.
    Clin Exp Pharmacol Physiol; 2009 Sep 10; 36(9):899-903. PubMed ID: 19298537
    [Abstract] [Full Text] [Related]

  • 13. The selective Hsp90 inhibitor BJ-B11 exhibits potent antitumor activity via induction of cell cycle arrest, apoptosis and autophagy in Eca-109 human esophageal squamous carcinoma cells.
    Liu KS, Zhang Y, Ding WC, Wang SX, Xiang YF, Yang P, Chen ZP, Zheng K, Liu Z, Xia M, Wang YF.
    Int J Oncol; 2012 Dec 10; 41(6):2276-84. PubMed ID: 23076967
    [Abstract] [Full Text] [Related]

  • 14. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.
    Cancer Sci; 2012 Feb 10; 103(2):342-9. PubMed ID: 22050138
    [Abstract] [Full Text] [Related]

  • 15. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.
    Proc Natl Acad Sci U S A; 2006 Nov 14; 103(46):17408-13. PubMed ID: 17090671
    [Abstract] [Full Text] [Related]

  • 16. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
    Iida S, Miki Y, Ono K, Akahira J, Nakamura Y, Suzuki T, Sasano H.
    Mol Cell Endocrinol; 2012 Mar 05; 350(1):99-106. PubMed ID: 22178087
    [Abstract] [Full Text] [Related]

  • 17. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
    Fraedrich K, Schrader J, Ittrich H, Keller G, Gontarewicz A, Matzat V, Kromminga A, Pace A, Moll J, Bläker M, Lohse AW, Hörsch D, Brümmendorf TH, Benten D.
    Clin Cancer Res; 2012 Sep 01; 18(17):4621-32. PubMed ID: 22753592
    [Abstract] [Full Text] [Related]

  • 18. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L, Walsby E, Gilkes A, Tonks A, Walsh V, Mills K, Burnett A, Rowntree C.
    Br J Haematol; 2008 May 01; 141(4):483-93. PubMed ID: 18373709
    [Abstract] [Full Text] [Related]

  • 19. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.
    Biochem Pharmacol; 2012 May 01; 83(9):1146-58. PubMed ID: 22285225
    [Abstract] [Full Text] [Related]

  • 20. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.